Actions of calcium ions and a calcium-influx blocker on basal and TRH- and GnRH-stimulated hormone release in patients with pituitary adenomas. 1987

M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville 22908.

We investigated the influence of calcium ions on the secretion of anterior pituitary hormones basally and in response to exogenous hypothalamic releasing factors in 6 men with pituitary tumors. To this end, concentrations of LH, FSH, TSH, growth hormone and prolactin were measured in blood collected at 10-min intervals basally and during a continuous infusion of combined TRH (2 micrograms/min) and GnRH (1 microgram/min). Study sessions were randomized to iv saline, calcium, or diltiazem infusions or oral diltiazem administration. Our results indicate that in contrast to responses in normal men, iv calcium injections do not suppress circulating prolactin concentrations in patients with prolactin-secreting pituitary tumors. Moreover, neither oral diltiazem administration for one week nor acute iv diltiazem infusion suppressed the hyperprolactinemia of tumor patients. However, there were significant effects of drug and calcium treatments on serum concentrations of FSH, GH and testosterone, but not LH or TSH. Moreover, during GnRH-TRH stimulation, there were significant differences in LH, TSH, and testosterone responses in tumor patients compared to normal men. In summary, iv calcium infusion was associated with invariant basal release of anterior pituitary tumoral hormones in patients with pituitary adenomas. However, there were significant differences in the GnRH/TRH-stimulated release of certain anterior pituitary hormones in tumor patients compared to normal men in response to iv calcium and the calcium-channel antagonist, diltiazem.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010903 Pituitary Gland, Anterior The anterior glandular lobe of the pituitary gland, also known as the adenohypophysis. It secretes the ADENOHYPOPHYSEAL HORMONES that regulate vital functions such as GROWTH; METABOLISM; and REPRODUCTION. Adenohypophysis,Anterior Lobe of Pituitary,Anterior Pituitary Gland,Lobus Anterior,Pars Distalis of Pituitary,Adenohypophyses,Anterior Pituitary Glands,Anterior, Lobus,Anteriors, Lobus,Lobus Anteriors,Pituitary Anterior Lobe,Pituitary Glands, Anterior,Pituitary Pars Distalis
D010906 Pituitary Hormone-Releasing Hormones Peptides, natural or synthetic, that stimulate the release of PITUITARY HORMONES. They were first isolated from the extracts of the HYPOTHALAMUS; MEDIAN EMINENCE; PITUITARY STALK; and NEUROHYPOPHYSIS. In addition, some hypophysiotropic hormones control pituitary cell differentiation, cell proliferation, and hormone synthesis. Some can act on more than one pituitary hormone. Hormones, Pituitary Hormone Releasing,Hypophysiotropic Hormones,Hypothalamic Hypophysiotropic Hormone,Hypothalamic Releasing Factor,Hypothalamic Releasing Hormone,Hypothalamic Releasing Hormones,Hormone, Hypothalamic Hypophysiotropic,Hormones, Hypophysiotropic,Hypophysiotropic Hormone, Hypothalamic,Pituitary Hormone Releasing Hormones,Releasing Hormone, Hypothalamic
D010908 Pituitary Hormones, Anterior Hormones secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Structurally, they include polypeptide, protein, and glycoprotein molecules. Adenohypophyseal Hormones,Anterior Pituitary Hormones,Hormones, Adenohypophyseal,Hormones, Anterior Pituitary
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
September 1984, Acta endocrinologica,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
November 1976, Clinical endocrinology,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
May 1981, Acta endocrinologica,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
April 1992, Endocrinology,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
June 1990, Clinical endocrinology,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
December 1978, Life sciences,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
March 1997, Journal of neuroendocrinology,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
April 1982, Acta endocrinologica,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
November 1987, The Journal of clinical endocrinology and metabolism,
M Davis, and B Nassberg, and J L Borges, and A Iranmanesh, and G Lizzaralde, and R J Santen, and C Drake, and A D Rogol, and D L Kaiser, and M O Thorner
February 1983, Clinical endocrinology,
Copied contents to your clipboard!